Admin, Author at Ology Bioservices Global CDMO

About Admin

This author has not yet filled in any details.
So far Admin has created 87 blog entries.

Ology Bioservices Strengthens Management Team with Addition of Timothy Cooke, Ph.D. as Senior Vice President of Commercial Business

Admin2019-04-15T17:50:38-04:00October 17th, 2018|

Ology Bioservices Strengthens Management Team with Addition of Timothy Cooke, Ph.D. as Senior Vice President of Commercial Business ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that industry veteran Timothy Cooke, Ph.D., has joined the Company as Senior Vice President of Commercial Business. “Tim brings [...]

Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure

Admin2019-04-15T17:50:47-04:00August 17th, 2018|

Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that it was awarded an Other Transaction Agreement (OTA) to support the Joint Project Manager Medical Countermeasure Systems (JPM-MCS), a component of the Joint [...]

Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases

Admin2018-08-10T10:19:56-04:00August 7th, 2018|

Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894. Read More >

Development of a synthetic Vi polysaccharide vaccine for typhoid fever

Admin2018-08-07T11:33:13-04:00August 7th, 2018|

Ni Y, Springer MJ, Guo J, et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine. 2017;35:7121–7126. Read Here >

An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E

Admin2018-08-10T10:18:32-04:00July 28th, 2018|

Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoSONE 2018.13(5):e0197011. Read Here >

Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.

Admin2018-07-30T10:58:50-04:00July 28th, 2018|

Ball JP, Springer MJ, Ni Y, Finger-Baker I, Martinez J, Hahn J, et al. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLoSONE. 2017;12(5):e0177310 Read Here >

Zika Virus: Medical Countermeasure Development Challenges.

Admin2018-08-07T11:52:05-04:00July 28th, 2018|

Malone RW, Homan J, Callahan MV, Glasspool-Malone J, Damodaran L, Schneider ADB, et al. Zika virus: medical countermeasure development challenges. 2016 PLoS Negl Trop Dis. 10(3): e0004530. Read Here >

Preclinical Dose Ranging Studies of a Novel Dry Powder Norovirus Vaccine Formulation

Admin2018-08-07T14:58:48-04:00July 25th, 2018|

Springer MJ, Ni Y, Finger-Baker I, et al. Preclinical dose ranging studies of a novel dry powder norovirus vaccine formulation. Vaccine. 2016;34(12):1452–1458. Read Here>

Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector

Admin2019-04-15T17:51:13-04:00July 24th, 2018|

Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents ALACHUA, Fla. & JERUSALEM--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), and Rafa Laboratories, Ltd. (Rafa), a leading Israeli pharmaceutical company, today announced that on July 9, 2018, [...]

Ology Bioservices to Develop Vaccine Candidate Against Malaria for The Global Health Initiative Fund

Admin2019-04-15T17:51:22-04:00July 14th, 2018|

Ology Bioservices will develop the large-scale, process development and manufacturing plan and supply the AnAPN1 vaccine candidate for use in ongoing pre-clinical studies and to prepare for subsequent clinical testing.

Previous 123 Next